Patient previously received allogeneic bone marrow or stem cell transplantation.
Prior bone marrow or peripheral blood stem cell transplantation within the last 6 (six) months
Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years of study start.
Extensive prior radiotherapy on more than 30% of bone marrow reserves or prior bone marrow/stem cell transplantation within 2 years before screening. Limited field radiation for ?2 weeks prior to screening period is permitted
Prior bone marrow or stem cell transplantation, or radiation therapy in more than 35% of bone marrow.
Participants must be designated to undergo reduced intensity allogeneic peripheral blood (PB) or bone marrow (BM) hematopoietic stem cell transplantation. Consent will be obtained prior to admission for HCT
History of organ, bone marrow, or stem cell transplantation
DONOR: Has undergone solid organ, stem cell, bone marrow or blood transplantation
Prior allogeneic bone marrow or peripheral blood stem cell transplantation
Prior hematopoietic stem cell or bone marrow transplantation
Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
Extensive prior RT on ?30% of bone marrow reserve as judged by the investigator or prior bone marrow/stem cell transplantation within 5 years before trial start.
Prior hematopoietic stem cell or bone marrow transplantation
Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
History of bone marrow or stem cell transplantation (allogeneic or autologous)
Patients with a history of histologically or pathologically confirmed diagnosis of AML and < 5% blasts in the peripheral blood or bone marrow (per bone marrow aspiration and/or biopsy within 6 weeks prior to screening) scheduled to undergo allogeneic stem cell transplantation
Patients with a histologically or pathologically confirmed diagnosis of MDS with < 10% blasts in the bone marrow (per bone marrow aspiration and/or biopsy within 6 weeks prior to screening) scheduled to undergo allogeneic stem-cell transplantation
Prior hematopoietic stem cell or bone marrow transplantation
Prior hematopoietic stem cell or bone marrow transplantation.
Extensive prior radiotherapy on more than 30 percent of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years from enrolment
Prior bone marrow or stem cell transplantation
Prior hematopoietic stem cell or bone marrow transplantation
History of bone marrow, stem cell, or allogenic organ transplantation
Eligible for allogeneic bone marrow or stem cell transplantation
Prior stem cell or bone marrow transplantation
Patients previously treated with autologous or allogeneic bone marrow or stem cell transplantation are ineligible
Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
Patients previously treated with allogeneic bone marrow or stem cell transplantation are ineligible
Prior allogeneic bone marrow or peripheral blood stem cell transplantation
History of previous bone marrow and/or stem cell transplantation.
Prior bone marrow/hematopoietic stem cell transplantation
History of receiving high-dose chemotherapy requiring bone marrow or stem cell support
History of previous bone marrow and/or stem cell transplantation.
Prior hematopoietic stem cell or bone marrow transplantation
Previous allogenic stem cell or allogeneic bone marrow transplantation
History of allogeneic bone marrow or stem cell transplantation
Extensive prior RT on more than 30 percent of bone marrow reserves (by Investigator judgment), or prior bone marrow/stem cell transplantation within 5 years before study start